Table 2 Associations of KRAS codons 12 and 13, and BRAF mutation status with clinicopathological and molecular characteristics
KRAS wild-type | Codon 12-mutated | Codon 13-mutated | p value | BRAF wild-type | BRAF-mutated | p value | |
|---|---|---|---|---|---|---|---|
334 (63.7) a | 156 (29.8) a | 34 (6.5) a | 446 (85.1) a | 78 (14.9) a | |||
Age | |||||||
Mean, median | 70.5, 71.4 | 70.9, 71.4 | 68.5, 69.6 | 0.297b | 70.2, 70.8 | 72.0, 73.1 | 0.017b |
Range | 51.5–85.6 | 50.9–84.0 | 49.8–83.7 | 49.8–86.6 | 51.5–84.3 | ||
Sex | |||||||
Female | 177 (53.0) | 83 (53.2) | 18 (52.9) | 0.999 | 227 (50.9) | 50 (64.1) | 0.031 |
Male | 157 (47.0) | 73 (46.8) | 16 (47.1) | 219 (49.1) | 28 (35.9) | ||
Tumour location | |||||||
Proximal | 101 (30.4) | 54 (34.6) | 10 (29.4) | 0.058 | 106 (23.8) | 59 (77.6) | <0.001 |
Transverse | 18 (5.4) | 0 (0) | 3 (8.8) | 11 (2.5) | 10 (13.2) | ||
Descending | 15 (4.5) | 12 (7.7) | 1 (2.9) | 24 (5.4) | 4 (5.3) | ||
Sigmoid | 66 (19.9) | 38 (24.4) | 7 (20.6) | 110 (24.7) | 1 (1.3) | ||
Rectum | 132 (39.8) | 52 (33.3) | 13 (38.2) | 195 (43.7) | 2 (2.6) | ||
Missing | 2 | - | - | 0 | 2 | ||
T stage | |||||||
1 | 32 (10.0) | 9 (6.0) | 4 (13.3) | 0.291 | 42 (9.9) | 3 (4.1) | 0.001 |
2 | 38 (11.9) | 18 (11.9) | 2 (6.7) | 52 (12.2) | 6 (8.1) | ||
3 | 201 (63.0) | 104 (68.9) | 16 (53.3) | 278 (65.3) | 43 (58.1) | ||
4 | 48 (15.0) | 20 (13.2) | 8 (26.7) | 54 (12.7) | 22 (29.7) | ||
Missing | 15 | 5 | 4 | 20 | 4 | ||
N stage | |||||||
0 | 180 (59.6) | 84 (57.9) | 15 (51.7) | 0.710 | 241 (59.7) | 37 (51.4) | 0.353 |
1 | 69 (22.8) | 39 (26.9) | 7 (24.1) | 97 (24.0) | 19 (26.4) | ||
2 | 53 (17.5) | 22 (15.2) | 7 (24.1) | 66 (16.3) | 16 (22.2) | ||
Missing | 32 | 12 | 5 | 42 | 6 | ||
M stage | |||||||
0 | 275 (84.1) | 128 (82.6) | 22 (64.7) | 0.018 | 366 (83.0) | 59 (78.7) | 0.363 |
1 | 52 (15.9) | 27 (17.4) | 12 (35.3) | 75 (17.0) | 16 (21.3) | ||
Missing | 17 | 1 | - | 5 | 3 | ||
Differentiation grade | |||||||
High | 20 (6.2) | 11 (7.1) | 0 (0) | 0.088 | 25 (5.7) | 5 (6.8) | <0.001 |
Intermediate | 222 (68.7) | 121 (77.6) | 26 (76.5) | 340 (77.4) | 30 (40.5) | ||
Low | 81 (25.1) | 24 (15.4) | 8 (23.5) | 74 (16.9) | 39 (52.7) | ||
Missing | 11 | - | - | 7 | 4 | ||
Vascular invasion | |||||||
No | 95 (51.1) | 45 (47.4) | 7 ( 38.9) | 0.561 | 125 (49.4) | 21 (46.7) | 0.735 |
Yes | 91 (48.9) | 50 (52.6) | 11 (61.1) | 128 (50.6) | 24 (53.3) | ||
Missing | 148 | 61 | 16 | 193 | 33 | ||
Tumour type | |||||||
Non-mucinous | 269 (82.0) | 114 (73.5) | 28 (84.8) | 0.073 | 360 (81.8) | 50 (65.8) | 0.001 |
Mucinous | 59 (18.0) | 41 (26.5) | 5 (15.2) | 80 (18.2) | 26 (34.2) | ||
Missing | 6 | 1 | 1 | 6 | 2 | ||
MSI screening status | |||||||
MSS | 245 (79.3) | 137 (96.5) | 31 (93.9) | <0.001 | 384 (93.2) | 29 (40.3) | <0.001 |
MSI | 64 (20.7) | 5 (3.5) | 2 (6.1) | 28 (6.8) | 43 (59.7) | ||
Missing | 25 | 14 | 1 | 24 | 6 | ||
Beta-catenin grades | |||||||
0–1 | 94 (29.7) | 37 (25.0) | 13 (38.2) | 0.470 | 99 (23.4) | 45 (59.2) | <0.001 |
2–3 | 108 (34.1) | 48 (32.4) | 9 (26.5) | 138 (32.6) | 26 (34.2) | ||
4–5 | 115 (36.3) | 63 (42.6) | 12 (35.3) | 186 (44.0) | 5 (6.6) | ||
Missing | 17 | 8 | - | 23 | 2 | ||
p53 status | |||||||
Negative | 169 (53.1) | 77 (51.3) | 12 (37.5) | 0.240 | 202 (47.6) | 57 (75.0) | <0.001 |
Positive | 149 (46.9) | 73 (48.7) | 20 (62.5) | 222 (52.4) | 19 (25.0) | ||
Missing | 16 | 6 | 2 | 22 | 2 | ||
p21 Expression | |||||||
Negative | 43 (13.7) | 22 (14.9) | 5 (15.2) | 0.931 | 63 (15.0) | 7 (9.2) | 0.180 |
Positive | 271 (86.3) | 126 (85.1) | 28 (84.8) | 356 (85.0) | 69 (90.8) | ||
Missing | 20 | 8 | 1 | 27 | 2 | ||
p27 Expression | |||||||
Negative | 58 (18.4) | 15 (10.1) | 9 (27.3) | 0.018 | 51 (12.1) | 31 (40.8) | <0 001 |
Positive | 258 (81.6) | 134 (89.9) | 24 (72.7) | 371 (87.9) | 45 (59.2) | ||
Missing | 18 | 7 | 1 | 24 | 2 | ||
Cyclin D1 expression | |||||||
Negative | 63 (20.0) | 23 (15.4) | 10 (30.3) | 0.129 | 90 (21.4) | 5 (6.6) | 0.003 |
Positive | 252 (80.0) | 126 (84.6) | 23 (69.7) | 331 (78.6) | 71 (93.4) | ||
Missing | 19 | 7 | 1 | 25 | 2 |